Navigation Links
Multiple Sclerosis drug, Tysabri banned due to neurological disorders

Tysabri, which is used in the treatment of Multiple Sclerosis (MS), has been withdrawn from market after the two patients taking the drug complained of neurological disorders. The relationship between the drug and // Progressive Multifocal Leukoencephalopathy (PML) is being researched by the scientists. If the drug is deemed to pose a significant risk, it could be a serious setback for the entire class of drugs, which work by blocking passage of immune cells in to the brain.

“Other cell migration inhibitors in development will have to be carefully tested, says Howard Weiner, director of the partners MS center at Brigham and Women’s Hospital. Several companies are developing drugs that use the same compounds to treat Crohn disease, rheumatoid arthritis and asthma. The US FDA has halted a phase 2 trial of a GlaxoSmithKline drug that targets the same protein, alpha-4 integrin, as Tysabri. Australian biotech Antisense Therapuetics stopped Phase 2 trial in March for similar MS drugs, which the company had also planned to develop as an asthma treatment. The FDA in November 2004 granted Tysabri fast track approval, after initial phase 3 results attacks by as much as 66%. Tysabri was expected to be a major blockbuster for its manufacturer Biogen Idec, but the company suspended sales of Tysabri in February, after learning of the two PML cases, one of which was fatal. The company also halted trials of the drug for rheumatoid arthritis and Crohn disease.

There has never previously been a documented case of PML in MS patients, even though these patients have been treated with many types of immunosuppresants. Both patients diagnosed with PML had taken Tysabri with Avonex, another MS drug, for two years n clinical trials.

Source: Nature Medicie
'"/>




Page: 1

Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated companies ... Gary D. Radine, who recently retired as president and CEO of Delta Dental of ... CEO of the Year , helped lead the effort to raise funds for studies ...
(Date:2/8/2016)... ... 08, 2016 , ... Eating disorders and post-traumatic stress disorder ... and men with eating disorders report a history of trauma, research suggests that ... an eating disorder. , At the 2016 iaedp Symposium, the workshop, “What ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... Vegas, Nevada (PRWEB) , ... February 08, 2016 ... ... at RowdMap, Inc., will be speaking on how healthcare companies can use newly ... costs, manage the health of a population and intervene and capture the value ...
(Date:2/8/2016)... ... 2016 , ... According to research by the National Association ... to be certified or obtain continuing education. To increase patient awareness of the ... Mouth?” campaign to inform dentists and patients about the possible lack of skills ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... /PRNewswire/--  Cell Applications, Inc. and Cyfuse Biomedical ... now available in North America ... approach called the "Kenzan Method." Utilizing Cyfuse Biomedical,s ... robotic system that fabricates 3D tissue from cells, ... model that makes scaffold-free tissue available immediately to ...
(Date:2/8/2016)... Velano Vascular, a medical technology company transforming ... their practitioners, announced today that the company has raised ... the proceeds from this financing, an extension of a ... to support the development and commercialization of the company,s ... Philadelphia , and a number ...
(Date:2/8/2016)... 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... delivery systems, today announced that it will release its financial ... 2015 after market close on February 9, 2016.  At this ... discuss these financial results.    About Unilife Corporation ... About Unilife Corporation UNIS ...
Breaking Medicine Technology: